Kovitz Investment Group Partners LLC lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 8.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,550 shares of the medical equipment provider’s stock after selling 2,100 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Hologic were worth $921,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Parnassus Investments CA raised its holdings in shares of Hologic by 88.6% during the fourth quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock valued at $608,797,000 after purchasing an additional 6,689,454 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Hologic during the third quarter valued at approximately $39,041,000. Two Sigma Advisers LP raised its holdings in shares of Hologic by 28.1% during the fourth quarter. Two Sigma Advisers LP now owns 2,828,311 shares of the medical equipment provider’s stock valued at $120,910,000 after purchasing an additional 620,761 shares during the last quarter. Guggenheim Capital LLC raised its holdings in shares of Hologic by 46.0% during the fourth quarter. Guggenheim Capital LLC now owns 1,662,053 shares of the medical equipment provider’s stock valued at $71,053,000 after purchasing an additional 523,654 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Hologic during the fourth quarter valued at approximately $18,383,000. Hedge funds and other institutional investors own 97.59% of the company’s stock.
Hologic, Inc. (NASDAQ HOLX) opened at $38.48 on Friday. The firm has a market cap of $10,629.78, a P/E ratio of 10.15, a price-to-earnings-growth ratio of 1.73 and a beta of 0.84. Hologic, Inc. has a 12-month low of $35.33 and a 12-month high of $46.80. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.25 and a quick ratio of 0.98.
Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.05. The business had revenue of $791.10 million during the quarter, compared to analyst estimates of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.52 earnings per share. sell-side analysts anticipate that Hologic, Inc. will post 2.25 EPS for the current year.
In other news, Director Namal Nawana purchased 6,600 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was acquired at an average cost of $37.88 per share, for a total transaction of $250,008.00. Following the completion of the transaction, the director now directly owns 6,954 shares in the company, valued at approximately $263,417.52. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company’s stock.
Several research analysts have recently weighed in on HOLX shares. Canaccord Genuity reissued a “buy” rating and set a $48.00 price objective on shares of Hologic in a report on Friday, February 9th. Needham & Company LLC reissued a “buy” rating and set a $50.00 price objective on shares of Hologic in a report on Friday, February 9th. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price for the company in a report on Thursday, January 4th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 target price for the company in a report on Wednesday, December 20th. Finally, Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $48.00.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.